Abstract:Objective:To investigate the influence factors of allograft acute rejection (AR) at the metaphase and long-term after kidney transplantation and the postoperative survival of allograft.Methods:The clinical data were retrospectively analysed in 43 recipients who accepted kidney transplantation were more than 1 years and were diagnosed with AR by allograft renal biopsy during January 2018 to December 2019. Seventeen of them with acute antibody-mediated rejection were as acute antibody rejection group, 26 of them with acute T cell-mediated rejection were as acute T cell rejection group, and 39 recipients who got kidney transplantation during the same period (in 2 weeks) were matched as control group. Paired sample t test or one-way ANOVA was used to compare the measurement data conforming to normal distribution among multiple groups. Chi-square test or Fisher exact probability was used for comparison between counting data groups. Kaplan-Meier was used for survival analysis and log-rank was used for comparison. A P<0.05 was considered statistically significant.Results:The proportion of 2 mismatches at HLA-A sites in HLA match before operation (4/17) was more higher in acute antibody rejection group than that in control group (1/39), and the difference was statistically significant (P=0.026). Serum creatinine and estimated glomerular filtration rate (eGFR) at the onset and last time of AR were higher in acute antibody rejection group and acute T cell rejection group than those before AR (all P<0.05). Serum creatinine and eGFR at the onset and last time of AR in acute antibody rejection and acute T cell rejection group were higher than those in control group (all P<0.05). The proportion of chronic kidney disease (CKD)-4 recipients in acute antibody rejection group was lower than that in acute T cell rejection group (χ2=5.73, P<0.05). The proportion of CKD-4 recipients in acute T cell rejection group and the proportion of renal allograft failure in acute antibody rejection group were higher than those in control group (χ2=17. 727 and 9.882, all P<0.05). When AR happened, the rate of PRA-Ⅰ positive recipients [41.2% (7/17)] and the rate of PRA-Ⅱ positive recipients [88.2% (15/17)] in acute antibody rejection group were both higher than those in acute T cell rejection group [11.5% (3/26) and 26.9% (7/26), respectively], the difference had statistical significance (P=0.042, P<0.001). The serum concentration of tacrolimus was significantly decreased in the acute antibody rejection group (3.72±0.76) ng/mL and in the acute T cell rejection group (3.37±0. 86) ng/mL when the AR occurred, which were all lower than that of the control group (5.73±1.25) ng/mL, the difference had statistical significance (all P<0.05), and also lower than the serum concentration of tacrolimus before AR occurred, the difference had statistical significance (t=7.120 and 6.216, all P<0.05). There were 4 recipients in the acute T cell rejection group used cyclosporine, and the serum concentration of cyclosporine of 3 recipients among them was not up to the mark at 33 (112.4 ng/mL), 36 (138.3 ng/mL) and 55 (7.0 ng/mL) months after transplantation. The serum concentration of cyclosporine of 2 recipients who used cyclosporine in the acute T cell rejection group was 43.2 (16 months after transplantation) and 24.6 ng/mL (177 months after transplantation), which were not up to the mark. All the recipients were followed up until June 30, 2021, the survival rate of transplant kidney of the acute antibody rejection group was lower than the control group (χ2=8.738, P<0.05).Conclusions:Mismatch at the HLA-A sites and the lower serum concentration of tacrolimus were the important factors for inducing AR in the metaphase and long-term after kidney transplantation. Acute antibody-mediated rejection was the important factor that affected the survival of transplant kidney.

Use of the ImmuKnow assay to evaluate the effect of alemtuzumab-depleting induction therapy on cell-mediated immune function after renal transplantation

Application of immune cell functional assay in monitoring immune status in renal transplant recipients

Efficacy and Safety of Induction Therapy with Alemtuzumab in Kidney Transplantation: A Meta-Analysis

Application of ImmuKnow immune cell function assay in monitoring of immune function after renal transplantation

Applications of the Examination for CD4+ T Cells' ATP in Renal Transplant Recipient

Application of Cell Immnune Function Monitoring by Cylex ImmuKnow Assay for Individual Immunosuppressive Therapy in Renal Transplantion Recipients

The significance of detecting the cell immune function in diagnosing the infection after renal transplantation using Cylex ImmuKnow assay

CD4+T lymphocytes intracellular adenosine triphosphate assay (Immuknow assay) and its application in solid organ transplantation

Persistently Low Immunereactivity As Determined by PHA-Induced ATP Release is Associated with Inferior Outcome in Allogeneic Hematopoietic Stem Cell Transplantation

Detection of Mass Concentrations of ATP in CD4 + T Cells for Immunity Monitoring in Renal Transplant Recipients

Clinical Study of Single-Dose of Recombinant Humanized Anti-Cd3 Monoclonal Antibody Injection in Kidney Transplant Recipients

Immune Cell Functional Assay in Monitoring of Adult Liver Transplantation Recipients with Infection

Phase I Trial Of A Humanized, Fc Receptor Nonbinding Anti-Cd3 Antibody, Hu12f6mu In Patients Receiving Renal Allografts

Clinical Analysis of 2520 Renal Transplantations in One Center

Long‐term outcomes of two‐dose alemtuzumab induction in pediatric kidney transplantation

Peripheral Blood CD 4 + Cell ATP Activity Measurement to Predict HCC Recurrence Post‐ DCD Liver Transplant

Increased Intracellular Adenosine Triphosphate Level As an Index to Predict Acute Rejection in Kidney Transplant Recipients

Efficiency of single-dose CD25 monoclonal antibody with low dose anti-human T-lymphocyte immunoglobulin in renal transplantation

Effect of Different Induction Therapies on the Clinical Outcomes of ABO-incompatible Living Donor Kidney Transplantation Recipients

245.5: Efficacy and Safety of an Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplant Recipients in China: A Prospective Cohort Study

Clinical study on allograft acute rejection at metaphase and long-term after kidney transplantation